Oligomeric amyloid β induces IL-1β processing via production of ROS: Implication in Alzheimer's disease

Cell Death and Disease

Volumn 4, Issue 12, 2013, Pages

  Parajuli, B ^a   Sonobe, Y ^a   Horiuchi, H ^a   Takeuchi, H ^a   Mizuno, T ^a   Suzumura, A ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

IL 1 ; microglia; NLRP3; oligomer A

Indexed keywords

AMYLOID BETA PROTEIN; CRYOPYRIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OLIGOMERIC AMYLOID BETA PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ATTENUATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; EMBRYO; ENZYME ACTIVITY; MICROGLIA; MITOCHONDRION; MOUSE; NEUROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; INTERLEUKIN-1BETA; MICE; MICROGLIA; REACTIVE OXYGEN SPECIES;

EID: 84891807547     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.503     Document Type: Article

References (53)

1. Walsh DM, Teplow DB. Alzheimer's disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 2012; 107: 101-124
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002; 297: 353-356
3. Selkoe D, Mandelkow E, Holtzman D. Deciphering Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: A011460
4. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC et al. Decreased clearance of CNS beta-Amyloid in Alzheimer's disease. Science 2010; 330: 1774
5. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 2005; 115: 1121-1129
6. Klug GM, Losic D, Subasinghe SS, Aguilar MI, Martin LL, Small DH. Beta-Amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH. Eur J Biochem 2003; 270: 4282-4293
7. Mastrangelo IA, Ahmed M, Sato T, Liu W, Wang C, Hough P et al. High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol 2006; 358: 106-119
8. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-6453
9. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853-862
10. Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K et al. Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis 2012; 29: 171-176
11. Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 2010; 37: 503-509
12. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2005; 2: 22
13. Rodriguez JJ, Witton J, Olabarria M, Noristani HN, Verkhratsky A. Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. Cell Death Dis 2010; 1: E1
14. Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J Neuroinflammation 2012; 9: 62
15. Weber A, Wasiliew P, Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci Signal 2010; 3, cm2
16. Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: Beyond the inflammasomes. PLoS Pathog 2010; 6: E1000661
17. Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: A danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19: 615-622
18. Stutz A, Golenbock DT, Latz E. Inflammasomes: Too big to miss. J Clin Invest 2009; 119: 3502-3511
19. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007; 14: 1583-1589
20. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W et al. The pyroptosome: A supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 2007; 14: 1590-1604
21. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221-225
22. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9: 857-865
23. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9: 847-856
24. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013; 493: 674-678
25. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A. Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer's pathology. J Cell Mol Med 2008; 12: 2255-2262
26. Terada K, Yamada J, Hayashi Y, Wu Z, Uchiyama Y, Peters C et al. Involvement of cathepsin B in the processing and secretion of interleukin-1beta in chromogranin A-stimulated microglia. Glia 2010; 58: 114-124
27. Dostert C, Guarda G, Romero JF, Menu P, Gross O, Tardivel A et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009; 4: E6510
28. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674-677
29. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, Hornung V. Cutting edge: Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 2011; 187: 613-617
30. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M et al. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol 2009; 175: 2121-2132
31. Parvathy S, Rajadas J, Ryan H, Vaziri S, Anderson L, Murphy GM Jr. Abeta peptide conformation determines uptake and interleukin-1alpha expression by primary microglial cells. Neurobiol Aging 2009; 30: 1792-1804
32. Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem 2011; 286: 3693-3706
33. Lindberg C, Selenica ML, Westlind-Danielsson A, Schultzberg M. Beta-Amyloid protein structure determines the nature of cytokine release from rat microglia. J Mol Neurosci 2005; 27: 1-12
34. Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH et al. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci USA 2008; 105: 1347-1352
35. Qin B, Cartier L, Dubois-Dauphin M, Li B, Serrander L, Krause KH. A key role for the microglial NADPH oxidase in APP-dependent killing of neurons. Neurobiol Aging 2006; 27: 1577-1587
36. Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation 2006; 3: 30
37. Abramov AY, Canevari L, Duchen MR. Beta-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004; 24: 565-575
38. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 2008; 14: 45-53
39. Sesti F, Liu S, Cai SQ. Oxidation of potassium channels by ROS: A general mechanism of aging and neurodegeneratioñ Trends Cell Biol 2010; 20: 45-51
40. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 2002; 418: 291
41. Yu SP, Farhangrazi ZS, Ying HS, Yeh CH, Choi DW. Enhancement of outward potassium current may participate in beta-Amyloid peptide-induced cortical neuronal death. Neurobiol Dis 1998; 5: 81-88
42. Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP et al. Microglial phagocytosis induced by fibrillar beta-Amyloid is attenuated by oligomeric beta-Amyloid: Implications for Alzheimer's disease. Mol Neurodegener 2011; 6: 45
43. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 2007; 117: 1595-1604
44. Moore AH, Wu M, Shaftel SS, Graham KA, O'Banion MK. Sustained expression of interleukin-1beta in mouse hippocampus impairs spatial memory. Neuroscience 2009; 164: 1484-1495
45. Vereker E, O'Donnell E, Lynch MA. The inhibitory effect of interleukin-1beta on long-Term potentiation is coupled with increased activity of stress-Activated protein kinases. J Neurosci 2000; 20: 6811-6819
46. Murray CA, Lynch MA. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age-And stress-induced impairments in longterm potentiation. J Neurosci 1998; 18: 2974-2981
47. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003; 23: 1605-1611
48. Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, LaFerla FM, Olschowka JA et al. Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci 2013; 33: 5053-5064
49. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 7611-7615
50. Craft JM, Watterson DM, Hirsch E, Van Eldik LJ. Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-Amyloid. J Neuroinflammation 2005; 2: 15
51. Suzumura A, Sawada M, Takayanagi T. Production of interleukin-12 and expression of its receptors by murine microglia. Brain Res 1998; 787: 139-142
52. Mizuno T, Doi Y, Mizoguchi H, Jin S, Noda M, Sonobe Y et al. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-beta neurotoxicity. Am J Pathol 2011; 179: 2016-2027
53. Parajuli B, Sonobe Y, Kawanokuchi J, Doi Y, Noda M, Takeuchi H et al. GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia. J Neuroinflammation 2012; 9: 268